Denali Therapeutics Inc. (DNLI) Return on equity 2017–2025
Denali Therapeutics Inc. (DNLI) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-50.6%FY2025 · since FY2017: -18.9% → -50.6%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -50.6% | -16.2 pp |
| FY2024 | -34.4% | -20.3 pp |
| FY2023 | -14.1% | +17.2 pp |
| FY2022 | -31.3% | -1.1 pp |
| FY2021 | -30.2% | -36.4 pp |
| FY2020 | 6.2% | +56.2 pp |
| FY2019 | -50.0% | -43.4 pp |
| FY2018 | -6.6% | +12.3 pp |
| FY2017 | -18.9% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More DNLI financial trends
DNLI RevenueDNLI Net incomeDNLI Net marginDNLI Gross profitDNLI Gross marginDNLI Operating incomeDNLI Operating marginDNLI Operating cash flowDNLI Free cash flowDNLI Capital expendituresDNLI Stock buybacksDNLI Dividends paidDNLI Total assetsDNLI Total liabilitiesDNLI Shareholders’ equityDNLI overview →